Search Within

Margaret Kathleen Callahan

Formats
  1. Journal Article (105)
  2. Meeting Abstract (84)
  3. Editorial (4)
  4. Book Section (2)
  5. Research Letter (2)
  6. Guidelines (1)
  7. Review (1)
Groups
  1. Department of Medicine (199)
  2. Melanoma and Immunotherapeutics Service (199)
  3. Solid Tumor Oncology Division (199)
  4. GSK Faculty (123)
  5. Melanoma Disease Management Team (108)
  6. Hematologic Malignancies, Division of (77)

More Groups

People
  1. Jedd Wolchok (113)
  2. Michael Postow (96)
  3. Paul Chapman (50)
  4. Alexander Shoushtari (46)
  5. Katherine Panageas (38)
  6. Parisa Momtaz (30)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (9)
  4. 2022 (13)
  5. 2021 (11)
  6. 2020 (19)

More Years

Publications
  1. Journal of Clinical Oncology (61)
  2. Journal for ImmunoTherapy of Cancer (17)
  3. Science Translational Medicine (10)
  4. Annals of Oncology (7)
  5. Clinical Cancer Research (7)
  6. New England Journal of Medicine (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (65)
  2. Biomed Central Ltd (17)
  3. American Association for Cancer Research (15)
  4. Elsevier Inc. (15)
  5. Oxford University Press (15)
  6. Nature Publishing Group (11)

More Publishers

Results (199)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy of nivolumab and ipilimumab (Nivo + Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP)
    Meeting Abstract

    Shoushtari, A. N.; Navid-Azarbaijani, P.; Friedman, C. F.; Panageas, K.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Campbell, S. C.; Shames, Y.; Prempeh-Keteku, N. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone
    Meeting Abstract

    Postow, M. A.; Kuk, D.; Adamow, M.; Carrera, C.; Wong, P.; Curran, M. A.; Friedman, C. F.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP)
    Meeting Abstract

    Friedman, C. F.; Navid-Azarbaijani, P.; Shoushtari, A. N.; Campbell, S. C.; Callahan, M. K.; Momtaz, P.; Prempeh-Keteku, N. A.; Postow, M. A.; Shames, Y.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+)
    Meeting Abstract

    Friedman, C. F.; Horvat, T. Z.; Minehart, J.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Appendiceal enlargement during immunotherapy treatment for melanoma
    Journal Article

    Bello, D. M.; Callahan, M. K.; Busam, K.; Ariyan, C. E.
    Clinical Skin Cancer (2016)

    Fulltext@MSK | Save
  • Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies
    Meeting Abstract

    Lipson, E.; Gopal, A.; Neelapu, S. S.; Armand, P.; Spurgeon, S.; Leonard, J. P.; Hodi, F. S.; Sanborn, R. E.; Melero, I.; Gajewski, T. F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Analysis of pharmacodynamic biomarkers in the first in-human trial of GITR co-stimulation with the agonist antibody TRX-518 in advanced solid cancer patients
    Meeting Abstract

    Zappasodi, R.; Li, Y.; Qi, J.; Wong, P.; Sirard, C.; Postow, M.; Newman, W.; Koon, H.; Velcheti, V.; Callahan, M. K.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study
    Meeting Abstract

    Sharma, P.; Callahan, M. K.; Calvo, E.; Kim, J. W.; de Braud, F.; Ott, P. A.; Bono, P.; Pillai, R. N.; Morse, M.; Le, D. T.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma
    Meeting Abstract

    Martin-Algarra, S.; Haanen, J. B.; Horak, C.; Bhatia, S.; Ribas, A.; Hwu, W. J.; Slingluff, C. L.; Sharfman, W. H.; Callahan, M.; Hodi, F. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save